{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:07:32Z","timestamp":1740179252470,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Under a societal perspective, disease and treatment attributes that the general public deem important should be considered within value frameworks. The objective was to investigate how members of the general public value attributes beyond health gains and healthcare system expenditures; and better understand their perspectives regarding the importance of attributes typically characterizing rare genetic diseases like Duchenne muscular dystrophy (DMD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Qualitative interviews were conducted to elicit feedback on the importance of disease and treatment attributes from general public participants from three US cities. Participants ranked attributes (scale, 1\u201310) in terms of importance for future research, reported their rationale for ranking, and provided feedback specific to rare diseases. Interview transcripts were coded using NVivo for thematic analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 33 participants (median age, 51\u00a0years; 48.5% male) ranked disease severity (mean [median] ranking, 8.7 [9.0]), treatment availability (8.7 [9.0]), and impact on life expectancy (8.4 [9.0]), as most important. The impact on the family, need for equity, and intrinsic value of life were frequently provided rationales. While rare disease as an attribute received a relatively low ranking (6.1 [7.0]), 88% of participants prioritized disease profiles including attributes of severity, health related quality of life (HRQoL) impact, limited lifespan and young age at onset.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Attributes including disease severity, impact on life expectancy and HRQoL, and treatment availability were all highly important to members of the general public. These findings support the growing evidence regarding the importance of expanding value assessments to include attributes considered important from a societal perspective.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-022-00413-6","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T13:10:05Z","timestamp":1643029805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Societal perspectives on disease and treatment attributes characterizing rare diseases: a qualitative study from the United States"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-3192","authenticated-orcid":false,"given":"Shelagh M.","family":"Szabo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana F.","family":"Audhya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Feeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"2","key":"413_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM (2018) Defining elements of value in health care-a health economics approach: an ISPOR Special Task Force Report [3]. Value Health 21(2):131\u2013139","journal-title":"Value Health"},{"issue":"2","key":"413_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jval.2016.11.013","volume":"20","author":"JS Mandelblatt","year":"2017","unstructured":"Mandelblatt JS, Ramsey SD, Lieu TA, Phelps CE (2017) Evaluating frameworks that provide value measures for health care interventions. Value Health 20(2):185\u2013192","journal-title":"Value Health"},{"key":"413_CR3","unstructured":"ICER (2020) 2020\u20132023 value assessment framework. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf. Accessed 20 Oct 21"},{"key":"413_CR4","unstructured":"Ollendorf D, Chapman R, Pearson S (2017) Assessing the effectiveness and value of drugs for rare conditions: a technical brief for the ICER orphan drug assessment & pricing summit: Institute for Clinical and Economic Review"},{"issue":"1","key":"413_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12955-018-1062-0","volume":"16","author":"L Uttley","year":"2018","unstructured":"Uttley L, Carlton J, Woods HB, Brazier J (2018) A review of quality of life themes in Duchenne muscular dystrophy for patients and carers. Health Qual Life Outcomes 16(1):237","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"413_CR6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A et al (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316(10):1093\u20131103","journal-title":"JAMA"},{"key":"413_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.socscimed.2014.12.023","volume":"126","author":"J van Exel","year":"2015","unstructured":"van Exel J, Baker R, Mason H, Donaldson C, Brouwer W, EuroVa QT (2015) Public views on principles for health care priority setting: findings of a European cross-country study using Q methodology. Soc Sci Med 126:128\u2013137","journal-title":"Soc Sci Med"},{"issue":"5","key":"413_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jval.2018.03.004","volume":"21","author":"S Nestler-Parr","year":"2018","unstructured":"Nestler-Parr S, Korchagina D, Toumi M et al (2018) Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR Rare Disease Special Interest Group. Value Health 21(5):493\u2013500","journal-title":"Value Health"},{"issue":"4","key":"413_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G","volume":"23","author":"M Sandelowski","year":"2000","unstructured":"Sandelowski M (2000) Whatever happened to qualitative description? Res Nurs Health 23(4):334\u2013340","journal-title":"Res Nurs Health"},{"issue":"6","key":"413_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19(6):349\u2013357","journal-title":"Int J Qual Health Care"},{"issue":"2","key":"413_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jval.2017.12.011","volume":"21","author":"RJ Willke","year":"2018","unstructured":"Willke RJ, Neumann PJ, Garrison LP Jr, Ramsey SD (2018) Review of recent US value frameworks-a health economics approach: an ISPOR Special Task Force Report [6]. Value Health 21(2):155\u2013160","journal-title":"Value Health"},{"key":"413_CR12","unstructured":"Avalere (2017) Avalere and fastercures release patient-perspective value framework to incorporate patient preferences into healthcare treatment decisions. https:\/\/avalere.com\/press-releases\/avalere-and-fastercures-release-patient-perspective-value-framework-to-incorporate-patient-preferences-into-healthcare-treatment-decisions. Accessed 26 Oct 21"},{"key":"413_CR13","unstructured":"Innovation and Value Initiative (2019) Open-source value project: transforming the process of value assessment. http:\/\/www.thevalueinitiative.org\/open-source-value-project\/. Accessed 26 Oct 21"},{"key":"413_CR14","unstructured":"National Institutes for Health and Clinical Excellence (2019) Highly specialised technologies guidance. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-highly-specialised-technologies-guidance. Accessed 30 Aug 2021"},{"key":"413_CR15","unstructured":"The National Institute for Health and Care Excellence (NICE). https:\/\/www.nice.org.uk\/about\/nice-communities\/nice-and-the-public\/public-involvement. Accessed 6 Oct 2021"},{"key":"413_CR16","unstructured":"Canadian Agency for Drugs and Therapeutics in Health (2016) Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives. Ottawa2013 [updated 2016 Feb]"},{"key":"413_CR17","unstructured":"Canadian Agency for Drugs and Therapeutics in Health (2019) The pCODR expert review committee (pERC). https:\/\/www.cadth.ca\/pcodr-expert-review-committee-perc. Accessed 22 Sep 2021"},{"key":"413_CR18","unstructured":"Australian Government Department of Health (2016) The Pharmaceutical Benefits Advisory Committee Guidelines. https:\/\/pbac.pbs.gov.au\/. Accessed 10 Nov 2021"},{"key":"413_CR19","unstructured":"Scottish Medicines Consortium (2018) How we make our decisions\/Submission guidelines. https:\/\/www.scottishmedicines.org.uk\/making-a-submission\/. Accessed 10 Nov 21"},{"issue":"7","key":"413_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J et al (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21(7):839\u2013842","journal-title":"Value Health"},{"issue":"1","key":"413_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L (2006) How many interviews are enough?: An experiment with data saturation and variability. Field Methods 18(1):59\u201382","journal-title":"Field Methods"},{"issue":"2","key":"413_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3(2):77\u2013101","journal-title":"Qual Res Psychol"},{"key":"413_CR23","doi-asserted-by":"publisher","first-page":"26152","DOI":"10.3402\/qhw.v9.26152","volume":"9","author":"V Braun","year":"2014","unstructured":"Braun V, Clarke V (2014) What can \u201cthematic analysis\u201d offer health and wellbeing researchers? Int J Qual Stud Health Well Being 9:26152","journal-title":"Int J Qual Stud Health Well Being"},{"issue":"1","key":"413_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G (2020) Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 15(1):141","journal-title":"Orphanet J Rare Dis"},{"key":"413_CR25","unstructured":"Food and Drug Administration of the United States (1983) Orphan Drug Act. USA"},{"key":"413_CR26","unstructured":"Health Canada (2018) About drugs and rare diseases in Canada. https:\/\/www.canada.ca\/en\/health-canada\/services\/licences-authorizations-registrations-drug-health-products\/regulatory-approach-drugs-rare-diseases\/about-drugs-rare-diseases.html"},{"issue":"6","key":"413_CR27","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","volume":"18","author":"T Richter","year":"2015","unstructured":"Richter T, Nestler-Parr S, Babela R et al (2015) Rare disease terminology and definitions\u2014a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health 18(6):906\u2013914","journal-title":"Value Health"},{"issue":"3","key":"413_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1017\/S1744133110000344","volume":"6","author":"E Mentzakis","year":"2011","unstructured":"Mentzakis E, Stefanowska P, Hurley J (2011) A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Health Econ Policy Law 6(3):405\u2013433","journal-title":"Health Econ Policy Law"},{"issue":"8","key":"413_CR29","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/hec.2872","volume":"22","author":"WG Linley","year":"2013","unstructured":"Linley WG, Hughes DA (2013) Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ 22(8):948\u2013964","journal-title":"Health Econ"},{"issue":"5","key":"413_CR30","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jval.2017.12.026","volume":"21","author":"SM Bourke","year":"2018","unstructured":"Bourke SM, Plumpton CO, Hughes DA (2018) Societal preferences for funding orphan drugs in the United Kingdom: an application of person trade-off and discrete choice experiment methods. Value Health 21(5):538\u2013546","journal-title":"Value Health"},{"issue":"5","key":"413_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0272989X17691744","volume":"37","author":"J Wiss","year":"2017","unstructured":"Wiss J, Levin LA, Andersson D, Tingh\u00f6g G (2017) Prioritizing rare diseases: psychological effects influencing medical decision making. Med Decis Mak 37(5):567\u2013576","journal-title":"Med Decis Mak"},{"key":"413_CR32","doi-asserted-by":"publisher","first-page":"c4715","DOI":"10.1136\/bmj.c4715","volume":"341","author":"AS Desser","year":"2010","unstructured":"Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS (2010) Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 341:c4715","journal-title":"BMJ."},{"issue":"5","key":"413_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jval.2018.03.010","volume":"21","author":"M Magalhaes","year":"2018","unstructured":"Magalhaes M (2018) Can severity outweigh smaller numbers? A deliberative perspective from Canada. Value Health 21(5):532\u2013537","journal-title":"Value Health"},{"issue":"2","key":"413_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/(SICI)1099-1050(199703)6:2<117::AID-HEC256>3.0.CO;2-B","volume":"6","author":"A Williams","year":"1997","unstructured":"Williams A (1997) Intergenerational equity: an exploration of the \u201cfair innings\u201d argument. Health Econ 6(2):117\u2013132","journal-title":"Health Econ"},{"issue":"4","key":"413_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14737167.2017.1277144","volume":"17","author":"SH Kwon","year":"2017","unstructured":"Kwon SH, Park SK, Byun JH, Lee EK (2017) Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea. Expert Rev Pharmacoecon Outcomes Res 17(4):411\u2013419","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"413_CR36","volume-title":"Cost-effectiveness in Health and Medicine","author":"JA Salomon","year":"2016","unstructured":"Salomon JA, Trikalinos TA, Sanders GD, Mandelblatt JS (2016) Identifying and quantifying the consequences of interventions. In: Neumann PJ, Russell LB, Siegel JE, Fariats TG (eds) Cost-effectiveness in Health and Medicine, 2nd edn. Oxford University Press, Oxford","edition":"2"},{"issue":"2","key":"413_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jval.2017.12.012","volume":"21","author":"PJ Neumann","year":"2018","unstructured":"Neumann PJ, Willke RJ, Garrison LP Jr (2018) A health economics approach to US value assessment frameworks-introduction: an ISPOR Special Task Force Report [1]. Value Health 21(2):119\u2013123","journal-title":"Value Health"},{"key":"413_CR38","first-page":"66","volume":"6","author":"SD Reed","year":"2021","unstructured":"Reed SD, Yang J-C, Gonzalez JM, Johnson FR (2021) Quantifying value of hope. Value Health 6:66","journal-title":"Value Health"},{"issue":"4","key":"413_CR39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1377\/hlthaff.2011.1300","volume":"31","author":"DN Lakdawalla","year":"2012","unstructured":"Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T (2012) How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff 31(4):676\u2013682","journal-title":"Health Aff"},{"issue":"6","key":"413_CR40","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s10508-012-0016-6","volume":"41","author":"SL Dworkin","year":"2012","unstructured":"Dworkin SL (2012) Sample size policy for qualitative studies using in-depth interviews. Arch Sex Behav. 41(6):1319\u20131320","journal-title":"Arch Sex Behav."},{"key":"413_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jobe.2014.12.001","volume":"1","author":"R Galvin","year":"2015","unstructured":"Galvin R (2015) How many interviews are enough? Do qualitative interviews in building energy consumption research produce reliable knowledge? J Build Eng 1:2\u201312","journal-title":"J Build Eng"},{"issue":"1","key":"413_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L (2006) How many interviews are enough? An experiment with data saturation and variability. Field Methods 18(1):59\u201382","journal-title":"Field Methods"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00413-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-022-00413-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00413-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T13:31:51Z","timestamp":1643031111000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-022-00413-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1186\/s41687-022-00413-6","relation":{},"ISSN":["2509-8020"],"issn-type":[{"type":"electronic","value":"2509-8020"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained prior to initiating data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided written informed consent prior to initiating the interview.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"NA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was funded by Sarepta Therapeutics. IFA and KLG are employees of Sarepta. SMS is an employee of Broadstreet HEOR, which received funds from Sarepta to conduct this study. DF, PN, and DCM received consulting fees related to this work. DF has a proprietary interest in Health Utilities Incorporated, Dundas, Ontario, Canada. HUInc. distributes copyrighted Health Utilities Index (HUI) materials and provides methodological advice on the use of HUI.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}